|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DBN1 |
Gene summary for DBN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DBN1 | Gene ID | 1627 |
| Gene name | drebrin 1 | |
| Gene Alias | D0S117E | |
| Cytomap | 5q35.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q16643 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1627 | DBN1 | LZE4T | Human | Esophagus | ESCC | 1.89e-14 | 3.86e-01 | 0.0811 |
| 1627 | DBN1 | LZE7T | Human | Esophagus | ESCC | 3.76e-04 | 6.40e-01 | 0.0667 |
| 1627 | DBN1 | LZE8T | Human | Esophagus | ESCC | 1.52e-09 | 3.50e-01 | 0.067 |
| 1627 | DBN1 | LZE20T | Human | Esophagus | ESCC | 1.68e-03 | 1.40e-01 | 0.0662 |
| 1627 | DBN1 | LZE22T | Human | Esophagus | ESCC | 2.97e-04 | 3.16e-01 | 0.068 |
| 1627 | DBN1 | LZE24T | Human | Esophagus | ESCC | 1.95e-16 | 5.57e-01 | 0.0596 |
| 1627 | DBN1 | LZE21T | Human | Esophagus | ESCC | 4.59e-02 | 2.53e-01 | 0.0655 |
| 1627 | DBN1 | LZE6T | Human | Esophagus | ESCC | 9.90e-04 | 3.64e-01 | 0.0845 |
| 1627 | DBN1 | P1T-E | Human | Esophagus | ESCC | 4.33e-04 | 3.36e-01 | 0.0875 |
| 1627 | DBN1 | P2T-E | Human | Esophagus | ESCC | 5.03e-51 | 9.52e-01 | 0.1177 |
| 1627 | DBN1 | P4T-E | Human | Esophagus | ESCC | 1.31e-32 | 7.53e-01 | 0.1323 |
| 1627 | DBN1 | P5T-E | Human | Esophagus | ESCC | 3.03e-27 | 4.87e-01 | 0.1327 |
| 1627 | DBN1 | P8T-E | Human | Esophagus | ESCC | 9.57e-08 | 1.73e-01 | 0.0889 |
| 1627 | DBN1 | P9T-E | Human | Esophagus | ESCC | 1.31e-14 | 3.95e-01 | 0.1131 |
| 1627 | DBN1 | P10T-E | Human | Esophagus | ESCC | 4.09e-32 | 5.94e-01 | 0.116 |
| 1627 | DBN1 | P11T-E | Human | Esophagus | ESCC | 4.66e-22 | 1.15e+00 | 0.1426 |
| 1627 | DBN1 | P12T-E | Human | Esophagus | ESCC | 3.61e-42 | 9.61e-01 | 0.1122 |
| 1627 | DBN1 | P15T-E | Human | Esophagus | ESCC | 2.08e-41 | 9.34e-01 | 0.1149 |
| 1627 | DBN1 | P16T-E | Human | Esophagus | ESCC | 8.07e-35 | 7.55e-01 | 0.1153 |
| 1627 | DBN1 | P17T-E | Human | Esophagus | ESCC | 3.68e-08 | 4.76e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001097614 | Thyroid | ATC | positive regulation of neuron projection development | 82/6293 | 163/18723 | 7.43e-06 | 7.61e-05 | 82 |
| GO:005196221 | Thyroid | ATC | positive regulation of nervous system development | 126/6293 | 272/18723 | 8.17e-06 | 8.27e-05 | 126 |
| GO:000836122 | Thyroid | ATC | regulation of cell size | 89/6293 | 181/18723 | 1.01e-05 | 1.00e-04 | 89 |
| GO:006099815 | Thyroid | ATC | regulation of dendritic spine development | 36/6293 | 61/18723 | 4.10e-05 | 3.32e-04 | 36 |
| GO:003051613 | Thyroid | ATC | regulation of axon extension | 51/6293 | 95/18723 | 4.33e-05 | 3.50e-04 | 51 |
| GO:010602716 | Thyroid | ATC | neuron projection organization | 50/6293 | 93/18723 | 4.87e-05 | 3.88e-04 | 50 |
| GO:004881315 | Thyroid | ATC | dendrite morphogenesis | 71/6293 | 146/18723 | 1.18e-04 | 8.38e-04 | 71 |
| GO:009706115 | Thyroid | ATC | dendritic spine organization | 45/6293 | 84/18723 | 1.27e-04 | 9.03e-04 | 45 |
| GO:006138712 | Thyroid | ATC | regulation of extent of cell growth | 56/6293 | 110/18723 | 1.30e-04 | 9.17e-04 | 56 |
| GO:006099911 | Thyroid | ATC | positive regulation of dendritic spine development | 26/6293 | 42/18723 | 1.60e-04 | 1.10e-03 | 26 |
| GO:009917314 | Thyroid | ATC | postsynapse organization | 78/6293 | 168/18723 | 3.66e-04 | 2.26e-03 | 78 |
| GO:006100114 | Thyroid | ATC | regulation of dendritic spine morphogenesis | 27/6293 | 47/18723 | 6.69e-04 | 3.77e-03 | 27 |
| GO:006099712 | Thyroid | ATC | dendritic spine morphogenesis | 33/6293 | 61/18723 | 7.76e-04 | 4.28e-03 | 33 |
| GO:006100311 | Thyroid | ATC | positive regulation of dendritic spine morphogenesis | 14/6293 | 20/18723 | 9.60e-04 | 5.13e-03 | 14 |
| GO:005122014 | Thyroid | ATC | cytoplasmic sequestering of protein | 15/6293 | 22/18723 | 9.63e-04 | 5.13e-03 | 15 |
| GO:009917512 | Thyroid | ATC | regulation of postsynapse organization | 44/6293 | 90/18723 | 1.89e-03 | 9.27e-03 | 44 |
| GO:003030719 | Thyroid | ATC | positive regulation of cell growth | 74/6293 | 166/18723 | 2.06e-03 | 9.73e-03 | 74 |
| GO:004863815 | Thyroid | ATC | regulation of developmental growth | 136/6293 | 330/18723 | 2.17e-03 | 1.02e-02 | 136 |
| GO:19026831 | Thyroid | ATC | regulation of receptor localization to synapse | 12/6293 | 18/18723 | 4.22e-03 | 1.79e-02 | 12 |
| GO:004592720 | Thyroid | ATC | positive regulation of growth | 106/6293 | 259/18723 | 7.90e-03 | 3.06e-02 | 106 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DBN1 | SNV | Missense_Mutation | c.1756N>A | p.Glu586Lys | p.E586K | Q16643 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DBN1 | SNV | Missense_Mutation | novel | c.661N>C | p.Glu221Gln | p.E221Q | Q16643 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| DBN1 | SNV | Missense_Mutation | rs558662294 | c.170N>T | p.Ser57Leu | p.S57L | Q16643 | protein_coding | tolerated(0.05) | possibly_damaging(0.865) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DBN1 | SNV | Missense_Mutation | novel | c.72N>C | p.Arg24Ser | p.R24S | Q16643 | protein_coding | tolerated_low_confidence(0.11) | benign(0.271) | TCGA-C8-A12U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DBN1 | SNV | Missense_Mutation | c.1231N>A | p.Ala411Thr | p.A411T | Q16643 | protein_coding | tolerated(0.16) | benign(0.015) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DBN1 | insertion | In_Frame_Ins | novel | c.678_679insAAATTCTGCCCTTCCCCACTCGCCAGCTCCTGGCAACGACCA | p.Arg226_Tyr227insLysPheCysProSerProLeuAlaSerSerTrpGlnArgPro | p.R226_Y227insKFCPSPLASSWQRP | Q16643 | protein_coding | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| DBN1 | insertion | Frame_Shift_Ins | novel | c.72_73insTT | p.Gln25PhefsTer42 | p.Q25Ffs*42 | Q16643 | protein_coding | TCGA-C8-A12U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DBN1 | SNV | Missense_Mutation | c.505G>C | p.Asp169His | p.D169H | Q16643 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DBN1 | SNV | Missense_Mutation | c.1028N>T | p.Ser343Phe | p.S343F | Q16643 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
| DBN1 | SNV | Missense_Mutation | novel | c.1879N>T | p.Pro627Ser | p.P627S | Q16643 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-LP-A4AU-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |